MedPath

Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-

Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
First Posted Date
2005-09-19
Last Posted Date
2010-08-04
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
32
Registration Number
NCT00193115

Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2005-09-19
Last Posted Date
2011-05-03
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
150
Registration Number
NCT00193011

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Non-Hodgkins Lymphoma
Interventions
First Posted Date
2005-09-19
Last Posted Date
2022-03-03
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
51
Registration Number
NCT00193479
Locations
🇺🇸

Tennessee Oncology, Nashville, Tennessee, United States

🇺🇸

Florida Cancer Specialists, Fort Myers, Florida, United States

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

Phase 2
Completed
Conditions
Estrogen Receptor-negative Breast Cancer
Estrogen Receptor-positive Breast Cancer
Progesterone Receptor-negative Breast Cancer
Progesterone Receptor-positive Breast Cancer
Stage IA Breast Cancer
Stage IB Breast Cancer
HER2-positive Breast Cancer
Stage IIIA Breast Cancer
Stage II Breast Cancer
Interventions
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: paclitaxel
Biological: filgrastim
Drug: capecitabine
Drug: methotrexate
Drug: vinorelbine tartrate
Procedure: needle biopsy
Procedure: therapeutic conventional surgery
Other: immunohistochemistry staining method
Biological: trastuzumab
Drug: tamoxifen citrate
Drug: letrozole
Other: laboratory biomarker analysis
First Posted Date
2005-09-19
Last Posted Date
2018-03-12
Lead Sponsor
University of Washington
Target Recruit Count
50
Registration Number
NCT00194779
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients

Phase 1
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2005-09-19
Last Posted Date
2009-11-20
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
103
Registration Number
NCT00190671
Locations
🇷🇺

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Saint Petersburg, Russian Federation

Efficacy of Steroid Versus Steroid Plus Cyclophosphamide for Severe Henoch-Schoenlein Purpura

Not Applicable
Completed
Conditions
Henoch-Schoenlein Purpura
Interventions
First Posted Date
2005-09-19
Last Posted Date
2011-05-04
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
200
Registration Number
NCT00190229
Locations
🇫🇷

Hôpital LARIBOISIERE, Paris, France

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Biological: trastuzumab
Drug: carboplatin
Drug: melphalan
Drug: cyclophosphamide
Procedure: adjuvant therapy
Drug: thiotepa
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Procedure: bone marrow ablation with stem cell support
Radiation: radiation therapy
First Posted Date
2005-09-16
Last Posted Date
2017-02-23
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
32
Registration Number
NCT00182793
Locations
🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma
Blood Cancer
Interventions
Procedure: Autologous hematopoietic cell transplant (Auto-HCT)
Procedure: Allogeneic hematopoietic cell transplant (Allo-HCT)
Drug: Cyclophosphamide
Drug: Filgrastim
Drug: Melphalan
Radiation: Total body irradiation (TBI)
Procedure: Cyclosporine (CSP)
Drug: Mycophenolate Mofetil (MMF)
First Posted Date
2005-09-16
Last Posted Date
2018-01-18
Lead Sponsor
Wen-Kai Weng
Target Recruit Count
63
Registration Number
NCT00185614
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

First Posted Date
2005-09-16
Last Posted Date
2008-04-23
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
42
Registration Number
NCT00187122
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Stem Cell Transplant for Hematological Malignancy

Not Applicable
Terminated
Conditions
Leukemia, Lymphocytic, Chronic
JMML
Leukemia, Myeloid, Chronic
AML
MDS
Non-hodgkin's Lymphoma
Leukemia, Lymphocytic, Acute
Multiple Myeloma
Hodgkin's Disease
Interventions
Biological: Stem Cell Transplant
Drug: Cyclophosphamide
Radiation: Total Body Irradiation
Drug: Busulfan
Biological: CD4+/CD25+ cells
Drug: Equine ATG (ATGAM)
First Posted Date
2005-09-15
Last Posted Date
2021-01-22
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
330
Registration Number
NCT00176930
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath